Dotinurad APIs offered by Loncom Pharma are emerging leaders in the treatment of hyperuricemia associated with gout. These APIs are distinguished by their selective urate reabsorption inhibition, which significantly lowers serum uric acid levels, providing relief from the pain and inflammation of gout.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
